專技 - 調劑學與臨床藥學題庫 下載題庫

30 下列那些藥物併用時可能因交互作用而增加心律不整的危險？
(A) Phenobarbital 和 Cisapride
(B) Ketoconazole 和 Phenobarbital
(C) Erythromycin 和 Terfenadine
(D) Carbamazepine 和 Terfenadine

專技 - 調劑學與臨床藥學- 91 年 - 91-1 專技檢覈_藥師：調劑學（包括臨床藥學與治療學）#11230

答案：C
難度： 簡單

討論
私人筆記( 0 )

	1F Bryan 國三上 (2014/03/31) Macrolides that may significantly inhibit CYP450 3A4 include clarithromycin, erythromycin, and troleandomycin. 檢舉
	2F Bonnie 大一下 (2019/06/18) 本品主成分 Terfenadine 為周邊專一性 H1 受體拮抗n劑。屬於無鎮靜作用或抗膽鹼激素作用的抗組織胺藥n物。因此不曾產生傳統抗組織胺所引起的昏睡、嗜眠n及鎮靜作用檢舉
	3F Bonnie 大一下 (2019/06/18) Title QT-prolonging Miscellaneous Agents (Highest Risk) / QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) Risk Rating D: Consider therapy modification Summary QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of QT-prolonging Miscellaneous Agents (Highest Risk). Severity Major Reliability Rating Fair Patient Management Consider alternatives to this combination. If use is necessary, monitor ... 查看完整內容 Title QT-prolonging Miscellaneous Agents (Highest Risk) / QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) Risk Rating D: Consider therapy modification Summary QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of QT-prolonging Miscellaneous Agents (Highest Risk). Severity Major Reliability Rating Fair Patient Management Consider alternatives to this combination. If use is necessary, monitor for QTc interval prolongation and arrhythmias (including torsades de pointes). Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these potentially life-threatening toxicities. QT-prolonging Miscellaneous Agents (Highest Risk) Interacting Members Arsenic Trioxide, Astemizole, Bedaquiline, Bepridil, ChlorproMAZINE, Cisapride, Delamanid, QuiNINE, Terfenadine, Ziprasidone QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) Interacting Members Ceritinib, Crizotinib, Erythromycin (Systemic) Exceptions Fluconazole, Nilotinib, Ribociclib 檢舉

你可以購買他人私人筆記。